Evidence map›Paper›PMID 34856876›Full record

ArticleHuman vaccines & immunotherapeutics2021

COVID-19 vaccine hesitancy among Mexican outpatients with rheumatic diseases.

Guillermo Guaracha-Basáñez, Irazú Contreras-Yáñez, Everardo Álvarez-Hernández, Carla Marina Román-Montes, Graciela Meza-López Y Olguín, María José Morales-Graciano, Salvador Saúl Valverde-Hernández, Ingris Peláez-Ballestas, Virginia Pascual-Ramos

Open access · bronzeAbstract read
In one paragraph

Article in Human vaccines & immunotherapeutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.2field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Guillermo Guaracha-BasáñezDepartment of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, CDMX, Mexico.
Irazú Contreras-YáñezDepartment of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, CDMX, Mexico.
Everardo Álvarez-HernándezDepartment of Rheumatology, Hospital General de México Dr. Eduardo Liceaga, CDMX, México.
Carla Marina Román-MontesInfectious Diseases Department, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, CDMX, México.
Graciela Meza-López Y OlguínDepartment of Rheumatology, Hospital General de México Dr. Eduardo Liceaga, CDMX, México.
María José Morales-GracianoDepartment of Rheumatology, Hospital General de México Dr. Eduardo Liceaga, CDMX, México.
Salvador Saúl Valverde-HernándezDepartment of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, CDMX, Mexico.
Ingris Peláez-BallestasDepartment of Rheumatology, Hospital General de México Dr. Eduardo Liceaga, CDMX, México.
Virginia Pascual-RamosDepartment of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, CDMX, Mexico.ORCID 0000-0002-7368-498X
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán · MXHospital General de México · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vaccine hesitancy (VH) has emerged as a recognized threaten to contain the COVID-19 pandemic. Historically, low vaccine acceptance rates had been described among patients with rheumatic diseases (RMDs). The study objective was to determine COVID-19 VH among Mexican outpatients with RMDs and validate the COVID-19 VH questionnaire. This cross-sectional study was developed in three steps. Step 1 consisted of translation/cultural adaptation of the Oxford-COVID-19-VH questionnaire. Step 2 consisted of pilot testing and questionnaire feasibility, content, construct and criterion validity, reliability (internal consistency and temporal stability) and questionnaire sensitivity to change. Step 3 consisted of VH phenomenon quantification in patients from two metropolitan tertiary-care-level centers. Step 1 followed ISPOR-task-force recommendations. Patients who participated in step 2 (n = 50 for pilot testing/feasibility and n = 208 for questionnaire validation [91 in test-retest and 70 in questionnaire-sensitivity to change]) and step 3 (n = 600) were representative outpatients with RMDs. The seven-item COVID-19 VH questionnaire was found feasible, valid (experts' agreement ≥80%; a 1-factor structure accounted for 60.73% of the total variance; rho = 0.156,

Indexed as

COVID-19Rheumatic DiseasesCOVID-19 VaccinesCross-Sectional StudiesHumansOutpatientsPandemicsReproducibility of ResultsSARS-CoV-2Surveys and QuestionnairesVaccination HesitancyCOVID-19 VaccinesCovid-19 vaccinerheumatic diseases patientsvaccine hesitancy

Identifiers

PMID34856876
PMCPMC8903992
OpenAlexW3215368361

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.